acute lymphoblastic leukaemia Archives -

Autolus Therapeutic Plc. (Nasdaq: AUTL), a clinical-stage biopharma and a portfolio company of Syncona Ltd., has announced that

Autolus announces primary endpoint met in FELIX trial, prices public offering

https://pharmaphorum.com/news/autolus-announces-primary-endpoint-met-in-felix-trial-prices-public-offering/

News/ News/ News/ Oncology/ R&D

Takeda’s Iclusig bests imatinib in first-line leukaemia trial

Phil Taylor acute lymphoblastic leukaemia, Iclusig, Novartis, Oncology, Takeda 0 Comment

Takeda has a chance of breaking into new territory with its blood cancer therapy Iclusig, after the drug

Takeda’s Iclusig bests imatinib in first-line leukaemia trial

https://pharmaphorum.com/news/takedas-iclusig-bests-imatinib-in-first-line-leukaemia-trial/

News/ News/ News/ Oncology/ Sales and Marketing

Gilead claims first CAR-T approval for leukaemia in older adults

Phil Taylor acute lymphoblastic leukaemia, Gilead Sciences, immuno-oncology, Kite Pharma, Kymriah, Novartis, Oncology, regulatory approval, Tecartus 0 Comment

Gilead Sciences’ Kite Pharma unit has carved out a niche for its CD19-targeted CAR-T therapy Tecartus in acute

Gilead claims first CAR-T approval for leukaemia in older adults

https://pharmaphorum.com/news/gilead-claims-first-car-t-approval-for-leukaemia-in-older-adults/

News/ News/ Oncology

Blackstone revs up Autolus’ CAR with $250m fuel injection

Phil Taylor acute lymphoblastic leukaemia, Autolus, Blackstone, CAR-T therapies, cell therapy, financing, immuno-oncology, Oncology 0 Comment

Private equity firm Blackstone has agreed to provide up to $250 million in financing to UK biotech Autolus

Blackstone revs up Autolus’ CAR with $250m fuel injection

https://pharmaphorum.com/news/blackstone-revs-up-autolus-car-with-250m-fuel-injection/

News/ News/ Oncology

Kite claims a first for CAR-T Tecartus in adult leukaemia

Phil Taylor acute lymphoblastic leukaemia, Gilead Sciences, immuno-oncology, Kite Pharma, Kymriah, Novartis, Oncology, regulatory approval, Tecartus 0 Comment

The FDA has approved Kite Pharma’s Tecartus as a treatment for adults with relapsed or refractory B-cell precursor

Kite claims a first for CAR-T Tecartus in adult leukaemia

https://pharmaphorum.com/news/kite-claims-a-first-for-car-t-tecartus-in-adult-leukaemia/

News/ News/ Oncology

ASCO21: Gilead sets up first FDA okay for CAR-T in adult ALL with Tecartus data

Phil Taylor acute lymphoblastic leukaemia, ASCO 2021, CAR-T therapies, Gilead Sciences, Kite Pharma, Kymriah, Novartis, Oncology, Tecartus 0 Comment

Novartis’ Kymriah has had the CAR-T therapy market for acute lymphoblastic leukaemia (ALL) to itself so far, but

ASCO21: Gilead sets up first FDA okay for CAR-T in adult ALL with Tecartus data

https://pharmaphorum.com/news/asco21-gilead-sets-up-first-fda-okay-for-adult-all-with-tecartus-data/

News/ News/ News/ Oncology/ Patients

Real-world data backs Kymriah’s safety profile, says Novartis

Phil Taylor acute lymphoblastic leukaemia, Haematology, Kymriah, Non-Hodgkins Lymphoma, Novartis, real world data 0 Comment

With more competition looming for its CAR-T therapy Kymriah, Novartis has pointed to new data that show the

Real-world data backs Kymriah’s safety profile, says Novartis

https://pharmaphorum.com/news/real-world-data-backs-kymriahs-safety-profile-says-novartis/

News/ News/ Oncology

Gilead expands CAR-T deal with MaxCyte, Precision files for $100m IPO

Richard Staines acute lymphoblastic leukaemia, blood cancer, cancer, CAR T, non-Hodgkin lymphoma, R&D 0 Comment

It has been a busy month already in the field of CAR-T therapy, with Gilead expanding a partnership

Gilead expands CAR-T deal with MaxCyte, Precision files for $100m IPO

https://pharmaphorum.com/news/gilead-expands-car-t-deal-with-maxcyte-precision-files-for-100m-ipo/

News/ News/ Oncology/ Top stories

Amgen’s blood cancer drug gets full EU licence

Richard Staines acute lymphoblastic leukaemia, Amgen, blood cancer 0 Comment

FDA granted full licence last year

Amgen’s blood cancer drug gets full EU licence

https://pharmaphorum.com/news/amgens-blood-cancer-drug-blincyto-licence/

Trending

acute lymphoblastic leukaemia

Login